Journal article
Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial
Abstract
IMPORTANCE: The optimal anticoagulant for patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) managed with an invasive strategy remains controversial.
OBJECTIVE: To compare the clinical efficacy and safety of otamixaban, a novel intravenous direct factor Xa inhibitor, with that of unfractionated heparin plus downstream eptifibatide in patients with NSTE-ACS undergoing a planned early invasive strategy.
Authors
Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM
Journal
JAMA, Vol. 310, No. 11, pp. 1145–1155
Publisher
American Medical Association (AMA)
Publication Date
September 18, 2013
DOI
10.1001/jama.2013.277165
ISSN
0098-7484
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Acute Coronary SyndromeAdultAgedAged, 80 and overAnticoagulantsCause of DeathCyclic N-OxidesDouble-Blind MethodEptifibatideFactor Xa InhibitorsFemaleHemorrhageHeparinHumansInfusions, IntravenousInjections, IntravenousMaleMiddle AgedMyocardial InfarctionPeptidesPercutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRiskSurvival AnalysisTreatment Outcome